References
- Kotowa W, Gatzemeier U, Pirk O, et al. A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. Journal of Medical Economics 2007; 10: 255–271
- Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications; Third Edition. 2005
- Hanna N, Shepherd FA, Fossela FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology 2004; 22: 1589–1597
- Shepherd FA, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. New England Journal of Medicine 2005; 353: 123–132
- Erlotinib Full Prescribing Information. Available at: http://www.gene.com/gene/products/information/oncology/tarceva/insert.jsp
- Shepherd FA, Pereira J, Ciuleanu T, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced NSCLC following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. [Slides kit] ASCO 2004 , Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=678
- SMC advice for Erlotinib (Tarceva) No. (220/05). 4 Nov 2005. Available at: http://www.scottishmedicines.org.uk/smc/files/erlotinib%20(Tarceva)%20FINAL%20Nov%2005%20(Amended%20221105)%20for%20website.pdf
- Docetaxel SPC. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=4594